For example, although only 20–25% of human breast cancers fall under the ErbB2 positive subtype, more than 45% of human non-invasive breast carcinomas can possess amplified and overexpressed ErbB2 suggesting that ErbB2 overexpression is more frequently associated with non-invasive disease [35]. Here, ERBB2 is linked to invasive breast carcinoma.